Abstract
IO monotherapies were approved and fully reimbursed for first-line (1L) therapy of unresectable advanced/metastatic NSCLC in February 2017 in Japan. Our aims were to describe treatment patterns and clinical outcomes for advanced NSCLC by regimen type in real-world clinical settings in Japan after the introduction of 1L IO monotherapy.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
